Abstract
Mass spectrometry plays a very visible role in biopharmaceutical industry, although its use in development, characterization, and quality control of protein drugs is mostly limited to the analysis of covalent structure (amino acid sequence and post-translational modifications). Despite the centrality of protein conformation to biological activity, stability, and safety of biopharmaceutical products, the expanding arsenal of mass spectrometry-based methods that are currently available to probe higher order structure and conformational dynamics of biopolymers did not, until recently, enjoy much attention in the industry. This is beginning to change as a result of recent work demonstrating the utility of these experimental tools for various aspects of biopharmaceutical product development and manufacturing. In this work, we use a paradigmatic protein drug interferon β-1a as an example to illustrate the utility of mass spectrometry as a powerful tool not only to assess the integrity of higher order structure of a protein drug, but also to predict consequences of its degradation at a variety of levels.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Modern Biopharmaceuticals: Design, Development, and Optimization, Vol. I–IV, Knäblein, J., Ed.; Wiley-VCH Verlag GmbH and Co., Weinheim, Germany
Volpi N. Therapeutic Applications of Glycosaminoglycans. Curr. Med. Chem. 2006, 13, 1799–1810.
Alvarez-Salas, L. M. Nucleic Acids as Therapeutic Agents. Curr. Top. Med. Chem. 2008, 8, 1379–1404.
Spada, S.; Walsh, G. Directory of Approved Biopharmaceutical Products; CRC Press: Boca Raton, 2005.
Leader, B.; Baca, Q. J.; Golan, D. E. Protein Therapeutics: A Summary and Pharmacological Classification. Nat. Rev. Drug Discov. 2008, 7, 21–39.
Stolnik, S.; Shakesheff, K. Formulations for Delivery of Therapeutic Proteins. Biotechnol. Lett. 2009, 31, 1–11.
Morozova-Roche, L.; Malisauskas, M. A False Paradise—Mixed Blessings in the Protein Universe: The Amyloid as a New Challenge in Drug Development. Curr. Med. Chem. 2007, 14, 1221–1230.
Maas, C.; Hermeling, S.; Bouma, B.; Jiskoot, W.; Gebbink, M. F. B. G. A Role for Protein Misfolding in Immunogenicity of Biopharmaceuticals. J. Biol. Chem. 2007, 282, 2229–2236.
Hughes, B. Gearing Up for Follow-On Biologics. Nat. Rev. Drug Discov. 2009, 8, 181.
Frank, R. G. Regulation of Follow-On Biologics. N. Engl. J. Med. 2007, 357, 841–843.
Dudzinski, D. M.; Kesselheim, A. S. Scientific and Legal Viability of Follow-On Protein Drugs. N. Engl. J. Med. 2008, 358, 843–849.
Serdyuk, I. N.; Zaccai, N. R.; Zaccai, G. Methods in Molecular Biophysics: Structure, Dynamics, Function; Cambridge University Press: Cambridge, UK, 2006.
Scapin, G. Structural Biology and Drug Discovery. Curr. Pharm. Design. 2006, 12, 2087–2097.
Petoukhov, M. V.; Svergun, D. I. Analysis of X-Ray and Neutron Scattering from Biomacromolecular Solutions. Curr. Opin. Struct. Biol. 2007, 17, 562–571.
Nguyen, L. T.; Wiencek, J. M.; Kirsch, L. E. Characterization Methods for the Physical Stability of Biopharmaceuticals. PDA J. Pharm. Sci. Technol. 2003, 57, 429–445.
Capelle, M. A. H.; Gurny, R.; Arvinte, T. High Throughput Screening of Protein Formulation Stability: Practical Considerations. Eur. J. Pharm. Biopharm. 2007, 65, 131–148.
Korotchkina, L. G.; Ramani, K.; Balu-Iyer, S. V. Folding Considerations for Therapeutic Protein Formulations. In Moelcular Biological Protein Folding, A; Elsevier Academic Press Inc.: San Diego, 2008; 255–270.
Zhang, Z.; Pan, H.; Chen, X. Mass Spectrometry for Structural Characterization of Therapeutic Antibodies. Mass Spectrom. Rev. 2009, 28, 147–176.
Srebalus-Barnes, C. A.; Lim, A. Applications of Mass Spectrometry for the Structural Characterization of Recombinant Protein Pharmaceuticals. Mass Spectrom. Rev. 2007, 26, 370–388.
Chowdhury, S. K.; Katta, V.; Chait, B. T. Probing Conformational Changes in Proteins by Mass Spectrometry. J. Am. Chem. Soc. 1990, 112, 9012–9013.
Loo, J. A.; Loo, R. R.; Udseth, H. R.; Edmonds, C. G.; Smith, R. D. Solvent-Induced Conformational Changes of Polypeptides Probed by Electrospray-Ionization Mass Spectrometry. Rapid Commun. Mass Spectrom. 1991, 5, 101–105.
Katta, V.; Chait, B. T. Conformational Changes in Proteins Probed by Hydrogen-Exchange Electrospray-Ionization Mass Spectrometry. Rapid Commun. Mass Spectrom. 1991, 5, 214–217.
Smith, R. D.; Lightwahl, K. J.; Winger, B. E.; Loo, J. A. Preservation of Noncovalent Associations in Electrospray Ionization Mass Spectrometry—Multiply Charged Polypeptide and Protein Dimers. Org. Mass Spectrom. 1992, 27, 811–821.
Ganem, B.; Li, Y. T.; Henion, J. D. Detection of Noncovalent Receptor Ligand Complexes by Mass Spectrometry. J. Am. Chem. Soc. 1991, 113, 6294–6296.
Kaltashov, I. A.; Eyles, S. J. Studies of Biomolecular Conformations and Conformational Dynamics by Mass Spectrometry. Mass Spectrom. Rev. 2002, 21, 37–71.
Back, J. W.; de Jong, L.; Muijsers, A. O.; de Koster, C. G. Chemical Cross-Linking and Mass Spectrometry for Protein Structural Modeling. J. Mol. Biol. 2003, 331, 303–313.
Hernandez, H.; Robinson, C. V. Determining the Stoichiometry and Interactions of Macromolecular Assemblies from Mass Spectrometry. Nat. Protoc. 2007, 2, 715–726.
Heck, A. J. R. Native Mass Spectrometry: A Bridge Between Interactomics and Structural Biology. Nat. Methods. 2008, 5, 927–933.
Yin, S.; Loo, J. A. Mass Spectrometry Detection and Characterization of Noncovalent Protein Complexes. Methods Mol. Biol. 2009, 492, 273–282.
Kaltashov, I. A.; Abzalimov, R. R. Do Ionic Charges in ESI MS Provide Useful Information on Macromolecular Structure?. J. Am. Soc. Mass Spectrom. 2008, 19, 1239–1246.
Hofstadler, S. A.; Sannes-Lowery, K. A. Applications of ESI-MS in Drug Discovery: Interrogation of Noncovalent Complexes. Nat. Rev. Drug Discov. 2006, 5, 585–595.
Atmanene, C.; Wagner-Rousset, E.; Malissard, M.; Chol, B.; Robert, A.; Corvaia, N.; Van Dorsselaer, A.; Beck, A.; Sanglier-Cianferani, S. Extending Mass Spectrometry Contribution to Therapeutic Monoclonal Antibody Lead Optimization: Characterization of Immune Complexes Using Noncovalent ESI-MS. Anal. Chem. 2009, 81, 6364–6373.
Zamani, L.; Lindholm, J.; Ilag, L. L.; Jacobsson, S. P. Discrimination Among IgG1-κ Monoclonal Antibodies Produced by Two Cell Lines Using Charge State Distributions in nanoESI-TOF Mass Spectra. J. Am. Soc. Mass Spectrom. 2009, 20, 1030–1036.
Hoofnagle, A. N.; Resing, K. A.; Ahn, N. G. Protein Analysis by Hydrogen Exchange Mass Spectrometry. Annu. Rev. Biophys. Biomol. Struct. 2003, 32, 1–25.
Eyles, S. J.; Kaltashov, I. A. Methods to Study Protein Dynamics and Folding by Mass Spectrometry. Methods. 2004, 34, 88–99.
Konermann, L.; Tong, X.; Pan, Y. Protein Structure and Dynamics Studied by Mass Spectrometry: H/D Exchange, Hydroxyl Radical Labeling, and Related Approaches. J. Mass Spectrom. 2008, 43, 1021–1036.
Engen, J. R. Analysis of Protein Conformation and Dynamics by Hydrogen/Deuterium Exchange MS. Anal. Chem., in press.
Kaltashov, I. A.; Bobst, C. E.; Abzalimov, R. R. H/D Exchange and Mass Spectrometry in the Studies of Protein Conformation and Dynamics: Is There a Need for a Top-Down Approach?. Anal. Chem. 2009, 81, 7892–7899.
Woods, V. L., Jr.; Hamuro, Y. High Resolution, High-Throughput Amide Deuterium Exchange-Mass Spectrometry (DXMS) Determination of Protein Binding Site Structure and Dynamics: Utility in Pharmaceutical Design. J. Cell. Biochem. 2001, 37S, 89–98.
Chalmers, M. J.; Busby, S. A.; Pascal, B. D.; He, Y.; Hendrickson, C. L.; Marshall, A. G.; Griffin, P. R. Probing Protein—Ligand Interactions by Automated Hydrogen/Deuterium Exchange Mass Spectrometry. Anal. Chem. 2006, 78, 1005–1014.
Tropak, M. B.; Kornhaber, G. J.; Rigat, B. A.; Maegawa, G. H.; Buttner, J. D.; Blanchard, J. E.; Murphy, C.; Tuske, S. J.; Coales, S. J.; Hamuro, Y.; Brown, E. D.; Mahuran, D. J. Identification of Pharmacological Chaperones for Gaucher Disease and Characterization of Their Effects on β-Glucocerebrosidase by Hydrogen/Deuterium Exchange Mass Spectrometry. Chem. BioChem. 2008, 9, 2650–2662.
Bobst, C. E.; Abzalimov, R. R.; Houde, D.; Kloczewiak, M.; Mhatre, R.; Berkowitz, S. A.; Kaltashov, I. A. Detection and Characterization of Altered Conformations of Protein Pharmaceuticals Using Complementary Mass Spectrometry-Based Approaches. Anal. Chem. 2008, 80, 7473–7481.
Houde, D.; Arndt, J.; Domeier, W.; Berkowitz, S.; Engen, J. R. Characterization of IgG1 Conformation and Conformational Dynamics by Hydrogen/Deuterium Exchange Mass Spectrometry. Anal. Chem. 2009, 81, 2644–2651.
Whitty, A.; Karpusas, M. The Structure of Human Interferon-β-1a (Avonex) and Its Relation to Activity: A Case Study of the Use of Structural Data in the Arena of Protein Pharmaceuticals. Protein Structure: Determination, Analysis, and Applications for Drug Discovery, Chasman, D. L., Ed.; Marcel Dekker: New York-Basel, 2003; pp 483–519.
Borden, E. C.; Sen, G. C.; Uze, G.; Silverman, R. H.; Ransohoff, R. M.; Foster, G. R.; Stark, G. R. Interferons at Age 50: Past, Current, and Future Impact on Biomedicine. Nat. Rev. Drug Discov. 2007, 6, 975–990.
Bermel, R. A.; Rudick, R. A. Interferon-β Treatment for Multiple Sclerosis. Neurotherapeutics. 2007, 4, 633–646.
Noseworthy, J. H.; Lucchinetti, C.; Rodriguez, M.; Weinshenker, B. G. Multiple Sclerosis. N. Engl. J. Med. 2000, 343, 938–952.
Kuprowski, M. C.; Konermann, L. Signal Response of Coexisting Protein Conformers in Electrospray Mass Spectrometry. Anal. Chem. 2007, 79, 2499–2506.
Dobo, A.; Kaltashov, I. A. Detection of Multiple Protein Conformational Ensembles in Solution via Deconvolution of Charge State Distributions in ESI MS. Anal. Chem. 2001, 73, 4763–4773.
Mohimen, A.; Dobo, A.; Hoerner, J. K.; Kaltashov, I. A. A Chemometric Approach to Detection and Characterization of Multiple Protein Conformers in Solution Using Electrospray Ionization Mass Spectrometry. Anal. Chem. 2003, 75, 4139–4147.
Davis, G. C.; Beals, J. M.; Johnson, C.; Mayer, M. H.; Meiklejohn, B. I.; Mitlak, B. H.; Roth, J. L.; Towns, J. K.; Veenhuizen, M. Recommendations Regarding Technical Standards for Follow-On Biologics: Comparability, Similarity, Interchangeability. Curr. Med. Res. Opin. 2009, 25, 1655–1661.
Karpusas, M.; Nolte, M.; Benton, C. B.; Meier, W.; Lipscomb, W. N.; Goelz, S. The Crystal Structure of Human Interferon β at 2.2 Å Resolution. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 11813–11818.
Orru, S.; Amoresano, A.; Siciliano, R.; Napoleoni, R.; Finocchiaro, O.; Datola, A.; De Luca, E.; Sirna, A.; Pucci, P. Structural Analysis of Modified Forms of Recombinant IFN-β Produced Under Stress-Simulating Conditions. Biol. Chem. 2000, 381, 7–17.
Claudinon, J.; Monier, M.-N.; Lamaze, C. Interfering with Interferon Receptor Sorting and Trafficking: Impact on Signaling. Biochimie. 2007, 89, 735–743.
Strunk, J. J.; Gregor, I.; Becker, Y.; Li, Z.; Gavutis, M.; Jaks, E.; Lamken, P.; Walz, T.; Enderlein, J.; Piehler, J. Ligand Binding Induces a Conformational Change in IFNAR1 that is Propagated to its Membrane-Proximal Domain. J. Mol. Biol. 2008, 377, 725–739.
Runkel, L.; deDios, C.; Karpusas, M.; Betzenhauser, M.; Muldowney, C.; Zafari, M.; Benjamin, C. D.; Miller, S.; Hochman, P. S.; Whitty, A. Systematic Mutational Mapping of Sites on Human Interferon-β1a that are Important for Receptor Binding and Functional Activity. Biochemistry. 2000, 39, 2538–2551.
Shoemaker, B. A.; Portman, J. J.; Wolynes, P. G. Speeding Molecular Recognition by Using the Folding Funnel: The Fly-Casting Mechanism. Proc. Natl. Acad. Sci. U.S.A.. 2000, 97, 8868–8873.
Xiao, H.; Kaltashov, I. A. Transient Structural Disorder as a Facilitator of Protein-Ligand Binding: Native H/D Exchange-Mass Spectrometry Study of Cellular Retinoic Acid Binding Protein I. J. Am. Soc. Mass Spectrom. 2005, 16, 869–879.
Griffith, W. P.; Kaltashov, I. A. Protein Conformational Heterogeneity as a Binding Catalyst: ESI-MS Study of Hemoglobin H Formation. Biochemistry. 2007, 46, 2020–2026.
Horn, J. R.; Kraybill, B.; Petro, E. J.; Coales, S. J.; Morrow, J. A.; Hamuro, Y.; Kossiakoff, A. A. The Role of Protein Dynamics in Increasing Binding Affinity for an Engineered Protein—Protein Interaction Established by H/D Exchange Mass Spectrometry. Biochemistry. 2006, 45, 8488–8498.
Seto, M. H.; Harkins, R. N.; Adler, M.; Whitlow, M.; Church, W. B.; Croze, E. Homology Model of Human Interferon-α8 and Its Receptor Complex. Protein Sci. 1995, 4, 655–670.
Chill, J. H.; Quadt, S. R.; Levy, R.; Schreiber, G.; Anglister, J. The Human Type I Interferon Receptor: NMR Structure Reveals the Molecular Basis of Ligand Binding. Structure. 2003, 11, 791–802.
Li, Z.; Strunk, J. J.; Lamken, P.; Piehler, J.; Walz, T. The EM Structure of a Type I Interferon—Receptor Complex Reveals a Novel Mechanism for Cytokine Signaling. J. Mol. Biol. 2008, 377, 715–724.
Arduini, R. M.; Strauch, K. L.; Runkel, L. A.; Carlson, M. M.; Hronowski, X.; Foley, S. F.; Young, C. N.; Cheng, W.; Hochman, P. S.; Baker, D. P. Characterization of a Soluble Ternary Complex Formed Between Human Interferon-β-1a and Its Receptor Chains. Protein Sci. 1999, 8, 1867–1877.
Jaitin, D. A.; Roisman, L. C.; Jaks, E.; Gavutis, M.; Piehler, J.; Van der Heyden, J.; Uze, G.; Schreiber, G. Inquiring into the Differential Action of Interferons (IFNs): An IFN-α2 Mutant with Enhanced Affinity to IFNAR1 is Functionally Similar to IFN-β. Mol. Cell. Biol. 2006, 26, 1888–1897.
Kalie, E.; Jaitin, D. A.; Podoplelova, Y.; Piehler, J.; Schreiber, G. The Stability of the Ternary Interferon—Receptor Complex Rather Than the Affinity to the Individual Subunits Dictates Differential Biological Activities. J. Biol. Chem. 2008, 283, 32925–32936.
Stadtman, E. R. Protein Oxidation and Aging. Free Radic. Res. 2006, 40, 1250–1258.
Houde, D.; Kauppinen, P.; Mhatre, R.; Lyubarskaya, Y. Determination of Protein Oxidation by Mass Spectrometry and Method Transfer to Quality Control. J. Chromatogr. A. 2006, 1123, 189–198.
Eaton, P. Protein Thiol Oxidation in Health and Disease: Techniques for Measuring Disulfides and Related Modifications in Complex Protein Mixtures. Free Radic. Biol. Med. 2006, 40, 1889–1899.
Gorman, J. J.; Wallis, T. P.; Pitt, J. J. Protein Disulfide Bond Determination by Mass Spectrometry. Mass Spectrom. Rev. 2002, 21, 183–216.
Lin, L. Betaseron. In Symposium on the Characterization of Biotechnology Pharmaceutical Products, Brown, F.; Lubiniecki, A.; Murano, G., Eds.; Karger: Washington, D.C., 1995; pp 97–104.
Runkel, L.; Meier, W.; Pepinsky, R. B.; Karpusas, M.; Whitty, A.; Kimball, K.; Brickelmaier, M.; Muldowney, C.; Jones, W.; Goelz, S. E. Structural and Functional Differences Between Glycosylated and NonGlycosylated Forms of Human Interferon-Beta (IFN-β). Pharm. Res. 1998, 15, 641–649.
Veronese, F. M.; Mero, A. The Impact of PEGylation on Biological Therapies. BioDrugs. 2008, 22, 315–329.
Pepinsky, R. B.; LePage, D. J.; Gill, A.; Chakraborty, A.; Vaidyanathan, S.; Green, M.; Baker, D. P.; Whalley, E.; Hochman, P. S.; Martin, P. Improved Pharmacokinetic Properties of a Polyethylene Glycol-Modified Form of Interferon-β-1a with Preserved In Vitro Bioactivity. J. Pharmacol. Exp. Ther. 2001, 297, 1059–1066.
Baker, D. P.; Lin, E. Y.; Lin, K.; Pellegrini, M.; Petter, R. C.; Chen, L. L.; Arduini, R. M.; Brickelmaier, M.; Wen, D.; Hess, D. M.; Chen, L.; Grant, D.; Whitty, A.; Gill, A.; Lindner, D. J.; Pepinsky, R. B. N-Terminally PEGylated Human Interferon-β-1a with Improved Pharmacokinetic Properties and In Vivo Efficacy in a Melanoma Angiogenesis Models. Bioconj. Chem. 2005, 17, 179–188.
Gaberc-Porekar, V.; Zore, I.; Podobnik, B.; Menart, V. Obstacles and Pitfalls in the PEGylation of Therapeutic Proteins. Curr. Opin. Drug Discov. Dev. 2008, 11, 242–250.
Roberts, M. J.; El Tayar, N.; McKenna, S.; Gorga, J.; Sawlivich, W. Site-selective modification of human interferon-β. AAPS J. 2000, 2(S1), 2140.
El-Tayar, N.; Roberts, M. J.; Harris, M.; Sawlivich, W. (2004) Polyol-IFN-β Conjugate and Composition Containing Same. U.S. Patent 2004/0043002 A1; Applied Research Systems, ARS Holdings, N.V., Curacao (NL), U.S.A.
Wrotnowski, C. Well-Characterized Biologicals: Trends and Views. Genet. Eng. News. 2000, 20, 21–74.
Prync, A. E. S.; Yankilevich, P.; Barrero, P. R.; Bello, R.; Marangunich, L.; Vidal, A.; Criscuolo, M.; Benasayag, L.; Famulari, A. L.; Dominguez, R. O.; Kauffman, M. A.; Diez, R. A. Two Recombinant Human Interferon-β-1a Pharmaceutical Preparations Produce a Similar Transcriptional Response Determined Using Whole Genome Microarray Analysis. Int. J. Clin. Pharmacol. Ther. 2008, 46, 64–71.
Wu, Y.; Engen, J. R.; Hobbins, W. B. Ultra Performance Liquid Chromatography (UPLC) Further Improves Hydrogen/Deuterium Exchange Mass Spectrometry. J. Am. Soc. Mass Spectrom. 2006, 17, 163–167.
Bobst, C. E.; Zhang, M.; Kaltashov, I. A. Existence of a Noncanonical State of Iron-Bound Transferrin at Endosomal pH Revealed by Hydrogen Exchange and Mass Spectrometry. J. Mol. Biol. 2009, 388, 954–967.
Sola, R. J.; Griebenow, K. Effects of Glycosylation on the Stability of Protein Pharmaceuticals. J. Pharm. Sci. 2009, 98, 1223–1245.
Holzman, D. C. Whatever Happened to Immunotoxins?: Research and Hope Are Still Alive. J. Natl. Cancer Inst. 2009, 101, 624–625.
Bagal, D.; Zhang, H.; Schnier, P. D. Gas-Phase Proton-Transfer Chemistry Coupled with TOF Mass Spectrometry and Ion Mobility-MS for the Facile Analysis of Poly(Ethylene Glycols) and PEGylated Polypeptide Conjugates. Anal. Chem. 2008, 80, 2408–2418.
Zheng, X.; Wu, S. L.; Hancock, W. S. Glycation of Interferon-β-1b and Human Serum Albumin in a Lyophilized Glucose Formulation: Part III: Application of Proteomic Analysis to the Manufacture of Biological Drugs. Int. J. Pharm. 2006, 322, 136–145.
Author information
Authors and Affiliations
Corresponding author
Additional information
Published online October 29, 2009
Rights and permissions
About this article
Cite this article
Kaltashov, I.A., Bobst, C.E., Abzalimov, R.R. et al. Conformation and dynamics of biopharmaceuticals: Transition of mass spectrometry-based tools from academe to industry. J Am Soc Mass Spectrom 21, 323–337 (2010). https://doi.org/10.1016/j.jasms.2009.10.013
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1016/j.jasms.2009.10.013